Lancet Neurol: Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers for Alzheimer's disease and frontotemporal degeneration

Plasma tau protein phosphorylation at threonine 217 (p-tau217) and plasma tau protein phosphorylation at threonine 181 (p-tau181) are related to the tau pathology of Alzheimer's disease
.

Recently, researchers have compared these two biomarkers in participants with normal cognition and patients with clinically diagnosed mild cognitive impairment, Alzheimer’s disease syndrome, or frontotemporal degeneration (FTLD) syndrome.

Plasma tau protein phosphorylation at threonine 217 (p-tau217) and plasma tau protein phosphorylation at threonine 181 (p-tau181) are related to the tau pathology of Alzheimer's disease

In this retrospective multi-cohort diagnostic performance study , the patients diagnosed with Alzheimer’s disease syndrome (Alzheimer’s disease dementia, logopenic variant primary progressive aphasia or posterior cortical Atrophy), FTLD syndrome (cortical basal ganglia syndrome, progressive supranuclear palsy, behavioral variant frontotemporal dementia, non-fluid variant primary progressive aphasia, or semantic variant primary progressive aphasia) , Or mild cognitive impairment; participants came from the University of California, San Francisco (UCSF) Memory and Aging Center, San Francisco, California, USA, and the Alliance for Advancement Research and Treatment of Frontotemporal Degeneration (ARTFL; 17 sites in the United States and two in Canada) Site)
.

In this retrospective multi-cohort diagnostic performance study , the patients diagnosed with Alzheimer’s disease syndrome (Alzheimer’s disease dementia, logopenic variant primary progressive aphasia or posterior cortical Atrophy), FTLD syndrome (cortical basal ganglia syndrome, progressive supranuclear palsy, behavioral variant frontotemporal dementia, non-fluid variant primary progressive aphasia, or semantic variant primary progressive aphasia) , Or mild cognitive impairment; retrospective multi-cohort diagnostic performance study

Participants from both cohorts were carefully characterized, including evaluation of CSF p-tau181, amyloid-PET or tau-PET (or both), as well as clinical and cognitive evaluation
.

Plasma p-tau181 and p-tau217 were measured using an electrochemiluminescence-based assay, which differed only in the specificity of the biotinylated antibody epitope

Participants from both cohorts were carefully characterized, including evaluation of CSF p-tau181, amyloid-PET or tau-PET (or both), as well as clinical and cognitive evaluation

• Between July 1 and November 30, 2020, data were collected from 593 participants (443 from UCSF and 150 from ARTFL, with an average age of 64 years [SD 13], 294 [50%] women)
  .
  
  Plasma p-tau217 is correlated with p-tau181 (r=0·90, p<0·0001)
  
  p-tau217 and p-tau181 have excellent diagnostic performance in distinguishing patients with Alzheimer's disease syndrome from other neurodegenerative diseases
  
  Leave a message here